Navigation Links
Pharmos Corporation Reports 2009 Second Quarter Results
Date:8/12/2009

ed a decrease in interest expense of $79,784 as the decrease is attributable to reduced debenture interest. In the first half of 2009 the Company recorded $166,930 in interest expense related to the issuance of $4,000,000 in convertible debentures issued on January 3, 2008.

The company believes that the current cash and cash equivalents totaling $2.9 million as of June 30, 2009 will be sufficient to support the currently planned continuing operations through at least December 31, 2009. The Company routinely pursues various funding options, including additional equity offerings, equity-like financing, strategic corporate alliances, business combinations and the establishment of product related research and development limited partnerships, to obtain additional financing to continue the development of its products and bring them to commercial markets. On April 21, 2009, the Company completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is $0.12 per share. If the trial is successful, this financing would also support additional efforts to negotiate a strategic partnership or license arrangement with a pharmaceutical company. This is consistent with Pharmos' strategy as previously communicated, since the Company does not have the resources to continue to develop Dextofisopam through a Phase 3 trial.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextof
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
6. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
7. Pharmos Completes Private Placement - Raises $1.8 Million
8. Pharmos Corporation Reports 2009 First Quarter Results
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body ... boot camp has held two charity workout events and is ... 26th, from 7:15 - 8:30 at Col Summers City Park, SE ... camp session raised $510 for Medical Teams International. Their second workout ... a Dream. On July 26th, Johnson and Portland Fit Body ...
(Date:7/11/2014)... 2014 As reported by Forbes in ... Are Genetics To Blame (6/30), Indino Downey has reportedly ... paraphernalia to smoke it with. His father, well-known actor ... son inherited from him may have something to do ... news during the 1980s and 1990s for substance abuse ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 ... today announces that he uses mini and full mouth ... offer the defining feature that distinguishes dental implants from ... in addition to the crowns. This alone prevents the ... also offer advantages related to comfort, appearance and ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... For breast cancer patients, the era of personalized medicine ... advances by USC Stem Cell researcher Min Yu and ... , In a July 11 study in Science ... breast cancer cells circulating through the blood streams of ... the "seeds" of metastasis, which travel to and establish ...
Breaking Medicine News(10 mins):Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2
... by the Canadian Association for Adolescent Health has found that ... are ignorant about important sex information.// ,The survey ... in casual sex and a half-million sexually active teens aged ... of teens claimed to have some knowledge about sex, but ...
... The infant formula Gentlease is being recalled from the market ... of metal particles in some cans. // So this brand ... makers of Gentlease powdered infant formula, Mead Johnson Nutritionals of ... batch number BMJ19 printed on the bottom of the cans. ...
... that swimming helps immensely the children to stay hale ... ,Researches conducted over six years at the Jigalong, ... examined the impact on children's health where swimming pools ... Institute for Child Health Research study found that at ...
... can do more than affecting just your gums. It ... premature delivery. // The following is the conclusion arrived ... York. ,Participants at the conference highlighted the ... association with gum disease. They further reflected the need ...
... level of which is strongly suggestive of prostate cancer in ... early signs of prostate cancer, // if any. A new ... needed for establishment of prostate cancer diagnosis in young men ... researchers from Duke University Medical Center analyzed more than 12,000 ...
... who is the principle investigator said that the new technique ... to discover molecules that can enhance or block different kinds ... succeeded in growing mature taste receptor cells outside the body. ... for a prolonged period of time. This is a break ...
Cached Medicine News:Health News:Unhealthy Gums Increase Risk Of Premature Delivery 2Health News:Functional Taste Cells Cultured In Vitro 2
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... BCR-ABL That Cause Resistance to Current ... CML and ALL ... ) today reported preliminary phase 1 data from an ongoing,trial of ... lymphocytic leukemia (Ph+ALL) who,are resistant to or intolerant of the approved ...
... Also Experienced Improved Physical Functioning, INDIANAPOLIS, June ... pain of the knee treated with 60 mg ... significant pain,reduction. Patients taking duloxetine reported significant pain ... treatment that lasted,throughout the 13-week trial.(1) Results from ...
Cached Medicine Technology:Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 2Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 3Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 3Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: